Dexcom (DXCM)
Health Care · Medical Devices / Diabetes Management · NASDAQ
Dexcom is a leading medical technology company specializing in continuous glucose monitoring (CGM) systems that help people with diabetes manage their condition with real-time data.
What Dexcom does
DexCom, Inc. is a medical device company focused on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for individuals with diabetes. Its technology provides real-time glucose data, enabling patients and healthcare providers to manage diabetes more effectively. The company offers various CGM products, including the Dexcom One, Dexcom One+, and Stelo lines, supported by data management and sharing tools like Dexcom Clarity and Dexcom Share.
Themes: diabetes care, digital health, wearable medical devices, remote patient monitoring
Fundamentals
- Price$84.41 as of 2026-10-08 close
- Market cap$31.9B as of 2026-07-23 (share count; price 2026-10-08)
- 1-year return+24.5% 2025-10-08 close $67.78 → 2026-10-08 close $84.41
- P/E33.60 as of 2026-10-08
- Net margin+17.9% FY2025, SEC XBRL
- Gross margin+60.1% FY2025, SEC XBRL
- ROE+30.5% FY2025, SEC XBRL
- Debt / equity0.49 as of 2026-09-03
- Revenue growth (YoY)+15.5% as of 2026-09-03
- Revenue CAGR (3y)+17.0% SEC XBRL
- Beta0.89 as of 2026-09-03
- Last reported earnings2026-07-30 SEC EDGAR Form 8-K (Item 2.02)
How DXCM compares in its sector
- price-to-earnings ratiomiddle range 185 covered Health Care peers, as of 2026-10-08
- net profit margintop 25% 430 covered Health Care peers, as of 2026-09-03
- operating margintop 25% 417 covered Health Care peers, as of 2026-09-03
- gross marginmiddle range 189 covered Health Care peers, as of 2026-09-03
- return on equitytop 10% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 10% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
DXCM is not currently in any published Top 10 list. Its scores are below.
Top 10 score
63.5 #137 of 1,379 scored · #17 of 151 in Health Care
Profitability 79th (return on equity 30.5%, operating margin 19.6%) and growth 74th (3-year revenue CAGR 17%, revenue growth year over year 15.5%); weakest is valuation (29th, price to book 12.2, price to earnings 33.6).
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
How Dexcom looks technically
Dexcom (DXCM) is trading 15.2% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 68 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 14, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 43, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 20 trading days ago. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 6% of the past ~6 months), which often precedes a bigger move.
Trend
8
| Distance from the 200-day | it is trading 15.2% above its 200-day average, the long-term trend line — a longer-term uptrend | +15.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $87.26 | $87.26 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $73.28 | $73.28 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 16 calendar days ago — the swings before that are what the structure reading is measured on | 16 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 90.385. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 68 trading days ago — a "golden cross", a bullish long-term signal | 68 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 14, below the 25 that marks a real trend) | 13.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 43, neither overbought (above 70) nor oversold (below 30) | 43.1 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($82.86 to $90.39) — its "stochastic" reading is 21 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 20.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 32 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $92.59 | $92.59 |
|---|---|---|
| From the 52-week high | it is 8.8% below its 52-week high (its highest price of the past year) | -8.8% |
| Above the 52-week low | it is 56.0% above its 52-week low (its lowest price of the past year) | +56.0% |
| Below the 52-week high | it is 8.8% below its highest point of the past year | 8.8% |
| Since a 20-day breakout | it made a new 20-day low about 20 trading days ago | 20 sessions |
| Since a 55-day breakout | it made a new 55-day high about 34 trading days ago | 34 sessions |
| All-time high | its highest closing price on record is $164.86 (set on 2021-11-18) | $164.86 |
| Given back of the 52-week move | over the past year its closes ranged ($54.84 to $92.34), and it has given back roughly a quarter of its rise from last year’s low — 21% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $67.97 to $69.17. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 21.1% |
| From the all-time high | it is 48.8% below its all-time high | -48.8% |
| Nearest price level | it is trading 1.4% below a resistance level at $85.57 — a price it turned at twice since 2025-02-04, most recently on 2025-07-15. Since 2024-10-08 it has 12 such levels below the current price and 4 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.4% |
| All-time low | its lowest closing price on record is $0.34 (set on 2008-11-20) | $0.34 |
| Above the all-time low | it is 24726.5% above its all-time low | +24,726% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 6% of the past ~6 months), which often precedes a bigger move | 6th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.23 between its high and its low — about 2.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.23 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $82.86 and $90.09 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $82.86 – $86.48 – $90.09 |
| Typical daily range (% of price) | its price moves about 2.7% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.6% |
| Stretch from the 200-day average | it is trading 5.0 daily ranges above its 200-day average price (15.2% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 5.0 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.97× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 1.9% since the prior reading | +1.9% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has softened toward "sell" since the prior reading | 0.02 toward sell |
Candlestick patterns
3
| Since a doji | 6 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 6 sessions ago |
|---|---|---|
| Since a hammer | today, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | today |
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 0.1% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.1% |
|---|---|---|
| Open gap | it gapped 7.3% above the previous close 48 sessions ago and has not traded back through the level it left behind at 74.54 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +7.3% |
| Gap filled | a 2.2% gap up opened on 2026-08-03 has been "filled" 45 sessions ago — price traded back through the level the gap left behind, and it took 2 sessions to close | 45 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +1.22% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 1.2 percentage points (the stock lost 0.1% while the market gained 1.0%) | -1.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 10.1 percentage points (the stock gained 14.0% while the market gained 3.8%) | +10.2% |
| vs market, 6 months | over the past 6 months this stock beat the market by 16.1 percentage points (the stock gained 33.5% while the market gained 17.5%) | +16.1% |
| vs market, 12 months | over the past 12 months this stock beat the market by 9.6 percentage points (the stock gained 24.5% while the market gained 15.0%) | +9.6% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is moderate, spanning 7.7% of the share price. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 15% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $73.22 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | +15.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% below the average price paid since it last reported on 2026-07-30 (its 10-Q), so the typical buyer over that stretch is under water. That average is $87.15 — a volume-weighted average of daily closes over 50 sessions, not a true tick-by-tick VWAP. | -3.1% |
Price levels it has turned at before
DXCM last closed at $84.41 on 2026-10-08. Since 2024-10-08 it has turned at 12 prices below its last close and 4 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $85.57 | Resistance | 1.4% above the last close | turned there twice · 2025-02-04 to 2025-07-15 |
| $82.43 | Support | 2.3% below the last close | turned there 9 times · 2024-12-04 to 2026-09-10 |
| $87.68 | Resistance | 3.9% above the last close | turned there six times · 2025-05-12 to 2026-08-26 |
| $89.88 | Resistance | 6.5% above the last close | turned there four times · 2025-01-27 to 2026-09-22 |
| $77.89 | Support | 7.7% below the last close | turned there three times · 2024-12-31 to 2026-06-08 |
| $75.90 | Support | 10.1% below the last close | turned there four times · 2024-10-25 to 2026-02-03 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $90.39.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $74.13 and $80.34 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $90.39.
This reading has stood for 8 trading days, since 2026-09-29.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · in a Bollinger Band volatility squeeze · trendless / choppy (low ADX) · Analyst price target recently RAISED · beating the market · Printed a hammer candle after a decline | Learn: moving average · golden cross · adx · rsi · breakout · bollinger bands
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.34 mean, 1=Strong Buy…5=Strong Sell) — 26 analysts
- Mean price target$96.23 range $79.00 – $115.00; median $95.00
Analyst estimates, as of 2026-10-08. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for DXCM
- Consensus EPS estimate$0.6731 next reporting period, as of 2026-10-08
- Estimate change, 30 days+$0.00208 (+0.3%) from $0.6711, on 2026-09-03, 35-day window
- Readings revised upward11% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on continued regulatory approvals and market acceptance of CGM technology.","Competitive pressure from other medical device companies in the diabetes management market.","Risks associated with reliance on specific manufacturing and supply chain processes."]
What changed in the latest 10-Q
AI-assisted comparison of DXCM's 10-Q filed 2026-07-30 against the prior one filed 2026-04-30.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-07-30) states there were no material changes to its critical accounting estimates during the six months ended June 30, 2026.
- Newer filing (2026-07-30) contains financial highlights for the three months ended June 30, 2026, including revenue of $1.31 billion, gross profit of $830.0 million, operating income of $318.3 million, net income of $249.1 million, and operating cash flow of $269.2 million.
- Newer filing (2026-07-30) reports cash, cash equivalents and short-term marketable securities totaling $1.95 billion at the end of the second quarter of 2026.
- Newer filing (2026-07-30) includes a financial overview table for the three months ended June 30, 2026 compared to the three months ended June 30, 2025.
- Removed:
- Older filing (2026-04-30) stated there were no material changes to its critical accounting estimates during the three months ended March 31, 2026.
- Older filing (2026-04-30) contained financial highlights for the three months ended March 31, 2026, including revenue of $1.19 billion, gross profit of $750.3 million, operating income of $255.3 million, net income of $199.5 million, and operating cash flow of $525.6 million.
- Older filing (2026-04-30) reported cash, cash equivalents and short-term marketable securities totaling $2.42 billion at the end of the first quarter of 2026.
- Older filing (2026-04-30) included a financial overview table for the three months ended March 31, 2026 compared to the three months ended March 31, 2025.
- Reworded:
- Newer filing (2026-07-30) changed the critical accounting estimates disclosure period from three months ended March 31, 2026 to six months ended June 30, 2026.
- Newer filing (2026-07-30) changed 'Other income, net' to 'Other income (expense), net' in the results of operations table.
- Newer filing (2026-07-30) added percentage-of-revenue column for net income in the results of operations table that was previously marked with asterisks in the older filing.
- Notes:
- The newer filing text is truncated and ends mid-sentence at '(1) The sum of the individual percenta', so changes after that point in the section could not be compared.
- The older filing text is also truncated near the end at the same footnote marker, so the remainder of that section is unavailable for comparison.
Risk Factors
- Added:
- Newer filing (2026-07-30) adds a new risk factor titled 'We cannot guarantee that the 2026 Share Repurchase Program will be fully consummated or that such program will enhance the long-term value of our share price.'
- Newer filing (2026-07-30) discloses that in May 2026, the Board of Directors authorized and approved the 2026 Share Repurchase Program for up to $1.00 billion of common stock with a repurchase period ending no later than June 30, 2027.
- Newer filing (2026-07-30) discloses that the Board terminated the existing share repurchase program with $250.0 million remaining available.
- Newer filing (2026-07-30) discloses that during the three and six months ended June 30, 2026, 8.6 million shares were repurchased under the 2026 Share Repurchase Program and no shares were repurchased under the 2025 Share Repurchase Program.
- Newer filing (2026-07-30) updates the repurchase table footnote (2) to add: 'In May 2026, our Board of Directors terminated the existing 2025 Share Repurchase Program, of which $250.0 million remained available to be repurchased under the program. No shares were repurchased under the 2025 Share Repurchase Program during the three months ended June 30, 2026. On May 14, 2026, we announced that our Board of Directors authorized and approved a share repurchase program of up to $1.00 billion of our outstanding common stock, with a repurchase period ending no later than June 30, 2027.'
- Newer filing (2026-07-30) updates the trading plans table (Item 5) to list Nicholas Augustinos (Director) adoption on 6/10/2026 of 8,089 shares expiring 8/10/2027; Sadie Stern (EVP, Chief People & Culture Officer) adoption on 5/28/2026 of 30,773 shares expiring 8/26/2027; and Jereme Sylvain (EVP, Chief Financial Officer) adoption on 6/10/2026 of 11,571 shares expiring 6/10/2027.
- Removed:
- Older filing (2026-04-30) includes in the trading plans table (Item 5) Jon Coleman, Mark Foletta, Jacob Leach, and Kevin Sayer adoptions, which are absent from the newer filing's trading plans table.
- Older filing (2026-04-30) includes footnote (2) in the trading plans table stating that Mark Foletta's adoption was 'Adopted on behalf of a trust for which Mr. Foletta serves as a trustee,' which is absent from the newer filing.
- Reworded:
- Older filing (2026-04-30) begins Item 1A by stating 'There were no material changes to the risk factors previously disclosed and included in our Annual Report on Form 10-K...' while newer filing (2026-07-30) changes this to 'The following risk factor supplements and, to the extent inconsistent, supersedes, the risk factors disclosed in Part I, Item 1A...'
- Newer filing (2026-07-30) changes 'in addition to the information set forth in this Quarterly Report on Form 10-Q' to 'in addition to the information and risk factors set forth in this Quarterly Report on Form 10-Q'.
- Notes:
- Comparison based only on the provided excerpts; the newer filing excerpt transitions from Item 1A into Items 2-6, while the older excerpt transitions from Item 1A into Items 2-6 as well. Changes in quarters reported (March 31 vs June 30) are inherently different due to the different reporting periods.
- The newer filing excerpt is truncated mid-Item 6 (exhibit list), which may omit additional comparative information present in the full filing.
- No materiality, legal, or investment conclusion is made; changes are described factually.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 15 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-05. The 4 days since 2026-10-05 have not been checked yet.
- Last 30 days · read to 2026-10-050 buys · 5 sells ($1M) — 4 selling insiders
- Last 90 days · read to 2026-10-050 buys · 15 sells ($7M) — 7 selling insiders
- Last 180 days · read to 2026-10-050 buys · 25 sells ($12M) — 8 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-28. Based on Form 4 filings read through 2026-10-05; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about DXCM's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 7 matched disclosures for DXCM from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
6 institutional 13F filers reported holding DXCM as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 66,071,048
- Reported value $4,449,885,054
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 5 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about DXCM's institutional holders → See what each manager we track holds →
Short interest (FINRA)
DXCM had 17,263,625 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
DXCM had 4.57% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.98 days to cover at the same settlement.
- Reported short interest (shares) 17,263,625
- Short interest (% of shares outstanding) 4.57%
- Prior settlement (shares) 17,626,435
- Reported change -2.06%
- Days to cover (reported) 4.98
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare DXCM vs…
Dexcom is found in…
Frequently asked questions
What does Dexcom (DXCM) do?
DexCom, Inc. is a medical device company focused on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for individuals with diabetes. Its technology provides real-time glucose data, enabling patients and healthcare providers to manage diabetes more effectively. The company offers various CGM products, including the Dexcom One, Dexcom One+, and Stelo lines, supported by data management and sharing tools like Dexcom Clarity and Dexcom Share.
What sector is Dexcom (DXCM) in?
Dexcom (DXCM) is classified in the Health Care sector. Its industry is Medical Devices / Diabetes Management. It trades on NASDAQ.
Who are Dexcom's (DXCM) competitors?
Notable peers of Dexcom (DXCM) include Abbott Laboratories, Medtronic and Senseonics Holdings. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in DXCM?
Yes — we hold 7 matched STOCK Act disclosures for DXCM from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Dexcom (DXCM) overbought or oversold right now?
Dexcom (DXCM) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 43, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on DXCM come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.